Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours

Ultra-sensitive EGFRT790Mdetection as an independent prognostic marker for lung cancer patients harboring EGFRdel19mutations and treated with first-generation TKIs

(2019) Julie vendrell et al.   CLINICAL CANCER RESEARCH

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer

(2019) Scott Kopetz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Low-dose triple drug combination targeting the PI3K/AKT/mTOR pathway and the MAPK pathway is an effective approach in ovarian clear cell carcinoma

(2019) Joseph J. Caumanns et al.   CANCER LETTERS

A Convergence-Based Framework for Cancer Drug Resistance

(2018) David J. Konieczkowski et al.   CANCER CELL

Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAF V600E -Mutant Colorectal Cancer

(2018) Ryan B. Corcoran et al.   Cancer Discovery

Clinical significance of repeat rebiopsy in detecting the EGFR T790M secondary mutation in patients with non-small cell lung cancer

(2018) Eiki Ichihara et al.   Oncotarget

Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor Organoids

(2018) Krijn K. Dijkstra et al.   CELL

Additivity of inhibitory effects in multidrug combinations

(2018) D. Russ et al.   Nature Microbiology

An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer

(2017) Yaohua Xue et al.   NATURE MEDICINE

Negative feedback regulation of the ERK1/2 MAPK pathway

(2016) David Lake et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Clinically Viable Gene Expression Assays with Potential for Predicting Benefit from MEK Inhibitors

(2016) Roz Brant et al.   CLINICAL CANCER RESEARCH

Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma

(2016) Chiara Ambrogio et al.   NATURE MEDICINE

Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition

(2016) Aaron N Hata et al.   NATURE MEDICINE

Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers

(2015) Sheng-Bin Peng et al.   CANCER CELL

Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models

(2015) C. A. Eberlein et al.   CANCER RESEARCH

Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer

(2015) E. M. Tricker et al.   Cancer Discovery

Feedback and redundancy in receptor tyrosine kinase signaling: relevance to cancer therapies

(2014) Chong Sun et al.   TRENDS IN BIOCHEMICAL SCIENCES

Lower gefitinib dose led to earlier resistance acquisition before emergence of T790M mutation in epidermal growth factor receptor-mutated lung cancer model

(2013) Hiromi Hayakawa et al.   CANCER SCIENCE

Safety and feasibility of targeted agent combinations in solid tumours

(2013) Sook Ryun Park et al.   Nature Reviews Clinical Oncology

Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors

(2013) E. J. Morris et al.   Cancer Discovery

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Crosstalk and Signaling Switches in Mitogen-Activated Protein Kinase Cascades

(2012) Dirk Fey et al.   Frontiers in Physiology

The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation

(2011) Michelle C. Mendoza et al.   TRENDS IN BIOCHEMICAL SCIENCES

A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations

(2010) Sreenath V. Sharma et al.   CELL

METRONOMIC CHEMOTHERAPY. CHANGING THE PARADIGM THAT MORE IS BETTER

(2009) O.Graciela Scharovsky et al.   Current Oncology

The RSK family of kinases: emerging roles in cellular signalling

(2008) Rana Anjum et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY